United States - English - NLM (National Library of Medicine)

akorn, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis . the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n.gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

United States - English - NLM (National Library of Medicine)

teligent pharma, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin topical solution is indicated for the topical treatment of acne vulgaris. erythromycin topical solution is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Canada - English - Health Canada

novopharm limited - erythromycin (erythromycin ethylsuccinate) - powder for solution - 200mg - erythromycin (erythromycin ethylsuccinate) 200mg - erythromycins

Canada - English - Health Canada

novopharm limited - erythromycin (erythromycin ethylsuccinate) - powder for solution - 100mg - erythromycin (erythromycin ethylsuccinate) 100mg - erythromycins

Canada - English - Health Canada

novopharm limited - erythromycin (erythromycin ethylsuccinate) - powder - 400mg - erythromycin (erythromycin ethylsuccinate) 400mg - erythromycins

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate, quantity: 468 mg (equivalent: erythromycin, qty 400 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate, quantity: 234 mg (equivalent: erythromycin, qty 200 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin topical solution usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical solution usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin topical solution, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical solution, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pinewood healthcare - erythromycin ethyl succinate - oral suspension - 25mg/1ml